Randomized phase II trial in prostate cancer with hormone-sensitive OligometaSTatic relapse: Combining stereotactic ablative radiotherapy and durvalumab (POSTCARD GETUG P13): Study protocol

BACKGROUND: As in other solid tumors, increasing evidence indicates that patients diagnosed with a limited number of prostate cancer metastases, so-called oligometastases, have a better prognosis than patients with extensive metastatic disease. Stereotactic body radiotherapy (SBRT) is now considered...

Descripción completa

Detalles Bibliográficos
Autores principales: Rogé, Maximilien, Pointreau, Yoann, Sargos, Paul, Meyer, Emmanuel, Schick, Ulrike, Hasbini, Ali, Rio, Emmanuel, Bera, Guillaume, Ruffier, Amandine, Quivrin, Magali, Chasseray, Mathieu, Latorzeff, Igor, Martin, Etienne, Guimas, Valentine, Pommier, Pascal, Leroy, Thomas, Ronchin, Philippe, Lepinoy, Alexis, Grand, Audrey, Cartier, Lysian, Didas, Ossama, Denis, Fabrice, Libois, Vincent, Blanc-Lapierre, Audrey, Supiot, Stéphane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10034400/
https://www.ncbi.nlm.nih.gov/pubmed/36968576
http://dx.doi.org/10.1016/j.ctro.2023.100613

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10034400/
https://www.ncbi.nlm.nih.gov/pubmed/36968576
http://dx.doi.org/10.1016/j.ctro.2023.100613

Ejemplares similares